Category: News

For Immediate Release June 9, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs; today confirmed that its COVID-19 mice study currently underway at the University of Georgia is progressing as planned. The study assesses the efficacy of two protease inhibitors in preventing transgenic mice challenged with  SARS-CoV-2 from progressing to illness and death. Should these studies prove successful, the  Company plans to file the data with the FDA and request authorization to do testing in actual  COVID-19 patients. Sunshine Biopharma’s protease inhibitor treatment is anticipated to be orally available, making it possible for the treatment to be in tablet form, which can be taken at home. 

“We are moving the project forward as fast as possible, albeit within the constraints of science,”  said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are optimistic that our research efforts will culminate in a drug that will help turn the page on the pandemic,” he added. 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.7 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds, which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs, making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine

Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release May 25, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate. Adva-27a  has been found to have two activities: (i) evasion of P-glycoprotein, and (ii) inhibition of  Topoisomerase II. P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types. By escaping the efflux pump of P-glycoprotein, Adva-27a is able to accumulate inside cancer cells and destroy them by inhibiting Topoisomerase II, a DNA unwinding enzyme preferentially used by cancer cells to multiply. 

Multidrug resistance is by far the biggest challenge in cancer therapy and P-glycoprotein is the major culprit. A plethora of anticancer drugs that are central to chemotherapeutic regimes are susceptible to the P-glycoprotein efflux activity. Among these are the vinca alkaloids (vinblastine  and vincristine), the taxanes (paclitaxel and docetaxel), the anthracyclines (doxorubicin and 

daunorubicin), the topoisomerase inhibitors (topotecan and etoposide), and the tyrosine kinase inhibitors (dasatinib and gefitinib). Sunshine Biopharma’s P-glycoprotein evading small molecule, Adva-27a, represents an effective alternative to all of these drugs. 

In addition, it has been recognized that most cancers consist of a heterogeneous population of drug-sensitive and drug-resistant cells. During the course of current chemotherapy regiments,  drug-sensitive cells are selectively destroyed and resistant cells become the dominant cancer cell population, leading to recurrence and metastasis. Unlike existing chemotherapy drugs,  Adva-27a is able to destroy both populations of cancer cells resulting in more complete eradication of the cancer being treated. 

“The implications of this development are vast in the context of cancer therapy as a whole,” said  Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited to soon have a new drug available for cancer sufferers around the world,” he added.  

About Sunshine Biopharma 

Sunshine Biopharma is focused on the research, development and commercialization of  oncology and antiviral drugs.

In the area of antiviral drugs, Sunshine Biopharma is currently engaged in the development of an oral treatment for COVID-19. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS CoV-2) is the causative agent of COVID-19, the ongoing pandemic that has claimed the lives of over 3.4 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine  Biopharma entered into an exclusive license agreement with the University of Georgia for two  Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the  University of Georgia, College of Pharmacy. The mice being used in the study have been  genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2)  transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV 

2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate.  The goal of the study is to determine if these protease inhibitors will protect the hACE2- transgenic mice from disease progression and death following infection with SARS-CoV-2.  Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I  clinical trial setting. 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact: Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected]

www.sunshinebiopharma.com

For Immediate Release May 20, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has paid off  $250,000 in variable rate convertible debt and is planning to soon eliminate the two similar items  remaining on the books of the Company. The Company’s application for uplisting to the OTCQB  had been declined due to outstanding variable rate loans which were on the Company’s  financial statements at the time of the application. The Company can re-apply in October 2021. 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are in the process of getting rid of  these loans to minimize dilution. Protecting the shareholders against harmful dilution is of  utmost importance to the management of Sunshine Biopharma.” 

Sunshine Biopharma continues to be a fully reporting issuer as it has been since inception. The  Company’s financial statements are audited by a PCAOB qualified firm and its quarterly and  annual reports are filed with the SEC under the same requirements as companies listed on the  OTCQB or any U.S. Stock Exchange. As a result of investments from RB Capital Partners, the  Company will be able to eliminate all harmful debt. This will leave the Company’s balance sheet  with only fixed price conversions. 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.4 million people worldwide  since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2

receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

In addition to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release May 13, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development, and  commercialization of oncology and antiviral drugs, announced that it has filed its 2021 first quarter report. The Report shows that the Company had Cash & Cash Equivalents of $1,796,596 as of  March 31, 2021, the period end. 

The following is a summary of the Report highlights: 

On January 26, 2021, the Company received a Notice of Allowance from the Canadian Intellectual  Property Office for a new patent application covering Adva-27a. The newly issued patent contains  new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033. 

On February 4, 2021, the Company entered into an exclusive license agreement with the  University of Georgia (“UGA”) for two Anti-Coronavirus compounds which UGA had previously  developed and patented. The Company and UGA will advance the development of these two  compounds in parallel with the Company’s own Anti-Coronavirus compound, SBFM-PL4. 

On March 1, 2021, the Company launched a new eCommerce website,  Nutrition.SunshineBiopharma.com. The site offers over 20 Science-Based Nutritional  Supplements products ranging from essential amino acids and rich protein powders to balanced  vitamins and crucial micronutrients. All of the Company’s Science-Based Nutritional Supplements  are manufactured and tested in Canada under GMP conditions. 

On March 9, 2021, the Company received a Notice of Allowance from the European Patent Office  for a new patent application covering Adva-27a. The newly issued patent contains new subject  matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent  patent in the United States was issued in 2019 (US Patent Number 10,272,065). 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are incredibly pleased with the  progress of our Company as a whole. We continue to receive positive interim results from the  University of Georgia regarding our mice study and the development of our Anti-Coronavirus  treatment, and are very happy about our expanded patents for Adva-27a.” 

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Sunshine Biopharma’s Adva-27a Anticancer Drug 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time.

For Additional Information Contact: Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] www.sunshinebiopharma.com 

Nutrition.SunshineBiopharma.com

For Immediate Release May 4, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has timely filed a nonprovisional patent application in the form of a PCT in the United States for its COVID-19  treatment under development. Sunshine had originally filed a provisional patent application  covering the COVID-19 treatment on May 22, 2020. This priority date has been maintained in the  newly filed PCT application. 

In addition to the original subject matter pertaining to inhibitors of the Main Coronavirus protease,  Mpro, the PCT application contains data and extends coverage to include the Papain-Like  Coronavirus protease, PLpro. The latter is an important antiviral target as it is involved in  suppression of the host immune system thereby leading to more severe illness. 

The etiologic agent of the current COVID-19 global pandemic is Severe Acute Respiratory  Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of  infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins  in infected human cells by cleaving them from two overlapping viral polyproteins, pp1a and pp1ab.  One of these functional proteins is a cysteine protease referred to as the main protease, Mpro (also called 3CLpro and nsp5). In addition to Mpro, a second cysteine protease, called PLpro, is  generated. Mpro and PLpro cleave the viral polyproteins at a number of specific sites thereby  generating several mature proteins essential for viral replication. PLpro also cleaves certain host  cell proteins resulting in suppression of the immune system and elevated morbidity. Because of  their functional indispensability in viral replication, Mpro and PLpro are attractive targets for the  development of anti COVID-19 therapy. 

In collaboration with the University of Georgia, College of Pharmacy, Sunshine has been pursuing  the development of several PLpro inhibitors and currently has two drug candidates of such under  evaluation in hACE2-transgenic mice. Sunshine anticipates that the COVID-19 treatment under  development will also be effective against the variants of concern. 

“The PCT represents a major milestone for our COVID-19 treatment project, as it strengthens our  intellectual property position and allows us to file patents on a worldwide basis going forward,”  said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.2 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. Sunshine Biopharma has  completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead  compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive  license agreement with the University of Georgia for two Anti-Coronavirus compounds which the  University of Georgia had previously developed and patented. The Company is currently  advancing the development of these two compounds in parallel with its own SBFM-PL4 by  conducting a transgenic mice study in collaboration with the University of Georgia, College of  Pharmacy. The mice being used in the study have been genetically engineered to express the  human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making  them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2  receptor to gain entry into human cells to replicate. The goal of the study is to determine if these  protease inhibitors will protect the hACE2-transgenic mice from disease progression and death  following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine  Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual  COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Adva-27a Anticancer Drug 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date  have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time.

For Additional Information Contact: Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected]

www.sunshinebiopharma.com

For Immediate Release April 22, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that RB Capital has injected an additional investment of $500,000 to augment the Company’s Coronavirus drug  development program. In addition, RB Capital has provided the Company with assurances that  it will continue to provide funding over the next 30 days for the Company’s other R&D activities,  including Ada-27a anticancer drug. 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are very pleased to continue our  relationship with RB Capital as long-term investor in the Company. They truly understand our  vision and are prepared to help us reach our exciting drug development objectives.” 

Deborah Braun of RB Capital Partners Inc. stated, “Given their recent success with initial mice  studies for their COVID-19 treatment, the tremendous progress with Adva-27a research and development, and the new e-commerce platform, we are happy to double our investment in  Sunshine Biopharma. We understand that financial resources are required to reach the various  milestones leadership has put into place for the Company and are pleased to support this  growth and progress. With this added investment the Company has the resources necessary to  bring these drugs to market faster than previously anticipated.” 

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by  computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of  the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such  molecules and identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine 

Biopharma entered into an exclusive license agreement with the University of Georgia for two  Anti-Coronavirus compounds which the University of Georgia had previously developed and  patented. The Company is currently advancing the development of these two compounds in  parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the  University of Georgia, College of Pharmacy. The mice being used in the study have been 

genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2)  transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV 2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate.  The goal of the study is to determine if these protease inhibitors will protect the hACE2- transgenic mice from disease progression and death following infection with SARS-CoV-2.  Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to  the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I  clinical trial setting. 

About Adva-27a Anticancer Drug 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release April 19, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed a Maximum Tolerated Dose (MTD) study in mice. Sunshine Biopharma is pleased to report that the MTD results are favourable and fall within the optimum range for use in humans. 

Next, Sunshine Biopharma will use the test dose indicated by these results to conduct the efficacy studies in hACE2-transgenic mice. 

Sunshine Biopharma’s COVID-19 treatment is an inhibitor of PLpro, a protease present only in the  SARS Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host innate immune system thereby causing significantly greater morbidity. 

“MTD is defined as the highest dose of a drug that does not cause unacceptable side effects or overt toxicity in a specific period of time. The MTD studies we conducted were designed with a  minimum number of animals and included endpoints such as clinical observations and blood tests for liver function,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are delighted that our compounds passed this critical toxicology step with flying colors,” he added. 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a patent application for several molecules which were designed to inhibit the Coronavirus  PLpro protease, thus shutting down the ability of the virus to multiply. PLpro is present only in the SARS  Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host’s innate immune system. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two additional Anti-Coronavirus compounds which the  University of Georgia had previously developed and patented. Sunshine Biopharma is currently advancing the development of these two compounds in parallel with the Company’s own (SBFM-PL4) by conducting a transgenic mice study in collaboration with the University of Georgia. The goal of the ongoing study is to determine if our protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine 

Biopharma plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Sunshine Biopharma’s Anticancer Compound 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release March 23, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received a total of  $2,054,000 to date from the recently announced committed minimum financing of $2,000,000 with  RB Capital Partners Inc. The financing is in the form of fixed-price convertible debt which now  stands at a weighted average conversion price of $0.43 per share. This debt is obligatorily convertible on or before the maturity date. 

The proceeds will be used for the ongoing development of the Company’s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer. Development of both projects is currently underway and the research is progressing as planned. On February 1, 2021, Sunshine Biopharma initiated a transgenic mice study for two Anti-Coronavirus compounds in collaboration with the University of Georgia. The goal of the ongoing study is to determine if these protease inhibitors will protect  the hACE2-transgenic mice from progression to disease and death following infection with SARS 

CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19  patient volunteers in a Phase I clinical trial setting. 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We continue to push ahead with the development of our COVID-19 treatment in collaboration with the University of Georgia and our  Adva-27a anticancer compound with our corporate partners in Montreal. This investment is integral to our progress in both of these crucial drug development sectors.” 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 2.7 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a patent application for several molecules which were designed to inhibit the Coronavirus  PLpro protease, thus shutting down the ability of the virus to multiply. PLpro is present only in the SARS  Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host’s innate immune system. On February 1, 2021, Sunshine Biopharma entered into an exclusive license  agreement with the University of Georgia for two additional Anti-Coronavirus compounds which the 

The University of Georgia had previously developed and patented. Sunshine Biopharma is currently advancing the development of these two compounds in parallel with the Company’s own (SBFM-PL4) by conducting a transgenic mice study in collaboration with the University of Georgia. The goal of the ongoing study is to determine if our protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine  Biopharma plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Sunshine Biopharma’s Anticancer Compound 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464

For Immediate Release March 11, 2021

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from the European Patent Office for a new patent application covering Adva-27a, the Company’s flagship anticancer compound. This newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United  States was issued in 2019 (US Patent Number 10,272,065) and similarly covers Adva-27a until  2033. The Canadian Intellectual Property recently issued a Notice of Allowance for the analogous patent in Canada. Sunshine Biopharma is the sole owner of all intellectual property rights pertaining to Adva-27a, including the first Adva-27a patent issued in the United States in 2012  (US Patent Number 8,236,935). 

“We are very excited about this significant extension of proprietary protection for Adva-27a,” said  Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “With a total population of nearly 450 million people, the European Union represents a significant market for Adva-27a once approved for marketing,” he added. 

About Sunshine Biopharma’s Adva-27a 

Adva-27a is a unique anticancer compound targeted for multidrug resistant cancer. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug  Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast  Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. 

About Sunshine Biopharma and COVID-19 Treatment 

In addition, to working on the development of Adva-27a, Sunshine Biopharma is engaged in the development of a treatment COVID-19. Severe Acute Respiratory Syndrome-Coronavirus-2  (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 2.6 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modelling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. On  February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the  University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. Sunshine Biopharma is currently advancing the development of these two compounds in parallel with the Company’s own SBFM-PL4 by conducting a  transgenic mice study in collaboration with the University of Georgia. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2  (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by  SARS-CoV-2. The SARSCoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if Sunshine Biopharma’s protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with  SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. The implications of a COVID-19 treatment becoming available are vast. This is particularly the case in view of the fact that some of the variants emerging around the world are more virulent and may escape neutralization by the current vaccines. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release March 4, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has received shipment  of a new batch of Adva-27a from its manufacturer in China. The material has been delivered to  the laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). 

Following initial QA/QC testing of the material for specific biological activity, Sunshine Biopharma  will proceed to performing tumor inhibition studies on xenograft mice harboring tumors of human  pancreatic cancer origin. Pancreatic Cancer is Sunshine Biopharma’s clinical trials indication for  Adva-27a. Among several other cancer types, Pancreatic Cancer is resistant to existing 

chemotherapy drugs but has been shown to be susceptible to Adva-27a in preclinical studies. 

“We look forward to initiating the xenograft mice studies as soon as the QA/QC testing is done.  Mice studies of this sort provide crucial information and technical guidance for the clinical trials to  be conducted in subsequent drug development events,” said Dr. Steve Slilaty, CEO of Sunshine  Biopharma. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19 which is now in the  transgenic mice testing phase, Sunshine Biopharma is engaged in the development Adva-27a, a  unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of  Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells,  Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for  Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General  Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual  property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming 

quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com